Faculty profile

Humphrey Fonge

ResearcherMedical ImagingUniversity of Saskatchewan

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Saskatchewan directory, so their courses may be missing. Find their university profile.

Humphrey Fonge

Researcher

Medical Imaging

Health Sciences

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
19 publications in the last five years, latest in 2026.
Senior (last) author on 13 recent papers, a sign of leading a research group.
Principal investigator on 4 research grants (4 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Radioimmunotherapy Actinium-225 Precision Medicine Antibody Drug Conjugates Alpha Particle Radiotherapy Immune Checkpoint Inhibitors Micropet/Ct Imaging Muc-16

Latest papers

Correction: Sekar et al. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. Int. J. Mol. Sci. 2021, 22, 9005.
International journal of molecular sciences · 2026
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.
International journal of pharmaceutics · 2026 · senior author
Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
British journal of cancer · 2026 · senior author

All 42 publications

Latest funding

Priming MUC-16 positive ovarian and pancreatic cancer cells for immunotherapy using an alpha particle labeled radioimmunoconjugate
CIHR · 2023 · Nominated PI
$979,200
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
CIHR · 2023 · Nominated PI
$62,500
Simultaneous targeting of multiple domains of HER2 and EGFR using domain-specific alpha particle labeled radioimmunoconjugates
CIHR · 2020 · Nominated PI
$970,020

All 4 grants and awards

42 publications.

Correction: Sekar et al. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. Int. J. Mol. Sci. 2021, 22, 9005.

Sekar S, Viswas RS, Miranzadeh Mahabadi H, Alizadeh E, Fonge H, Taghibiglou C

International journal of molecular sciences2026

DOI: 10.3390/ijms27135650 PMID: 42450359

Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.

Njotu FN, Garcia MD, Nwangele E, Babeker H, Pougoue Ketchemen J, Doroudi A, Price EW, Gordon JR, Uppalapati M, Fonge H

International journal of pharmaceutics2026Senior author

DOI: 10.1016/j.ijpharm.2026.126923 PMID: 42055153

Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.

Pougoue Ketchemen J, Monzer A, Njotu FN, Babeker H, Tikum AF, Nwangele E, Henning N, Hassani N, Ngong AF, Doroudi A, Fonge H

British journal of cancer2026Senior author

DOI: 10.1038/s41416-026-03393-2 PMID: 41946831

Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage.

Das A, Florence T, Rodrigues CR, Ambros B, Singh J, Fonge H, Aulakh GK

Nuclear medicine and biology2026

DOI: 10.1016/j.nucmedbio.2026.109633 PMID: 42114414

[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.

Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H

Breast cancer research : BCR2026Senior author

DOI: 10.1186/s13058-026-02220-z PMID: 41546059

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.

Pougoue Ketchemen J, Ahenkorah S, Nwangele E, Malaza SSP, Ooms M, Cardinaels T, Leekens S, Cleeren F, Fonge H

EJNMMI radiopharmacy and chemistry2025Senior author

DOI: 10.1186/s41181-025-00408-w PMID: 41428153

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

Tikum AF, Henning NW, Pougoue Ketchemen J, Doroudi A, Babeker H, Njotu FN, Nwangele E, Monzer A, Gray B, Torlakovic E, Uppalapati M, Fonge H

Cancer research2025Senior author

DOI: 10.1158/0008-5472.can-24-2266 PMID: 40126545

225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.

Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, Nwangele E, Uppalapati M, Fonge H

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025Senior author

DOI: 10.2967/jnumed.124.268387 PMID: 39978811

Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.

Njotu FN, Pougoue Ketchemen J, Babeker H, Henning N, Tikum AF, Nwangele E, Monzer A, Hassani N, Gray BD, Pak KY, Torlakovic EE, Uppalapati M, Fonge H

European journal of nuclear medicine and molecular imaging2025Senior author

DOI: 10.1007/s00259-024-07011-2 PMID: 39627348

Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.

Pougoue Ketchemen J, Njotu FN, Babeker H, Monzer A, Nwangele E, Tikum AF, Henning N, Hassani N, Frye S, Perron R, Byrne C, Didychuk C, Qi Q, Bannister L, Doroudi A, Fonge H

Clinical cancer research : an official journal of the American Association for Cancer Research2025Senior author

DOI: 10.1158/1078-0432.ccr-24-1779 PMID: 39670857

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Radioimmunotherapy Dear Professor Fonge, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Correction: Sekar et al. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. Int. J. Mol. Sci. 2021, 22, 9005." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Priming MUC-16 positive ovarian and pancreatic cancer cells for immunotherapy using an alpha particle labeled radioimmunoconjugate" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Humphrey Fonge

Research

Latest papers

Latest funding

Correction: Sekar et al. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. Int. J. Mol. Sci. 2021, 22, 9005.

Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.

Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.

Development of angiostatin based radiopharmaceutical as a sensitive tool for detection of ATP synthase during acute vascular damage.

[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks.

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.

Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.

Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.

Priming MUC-16 positive ovarian and pancreatic cancer cells for immunotherapy using an alpha particle labeled radioimmunoconjugate

225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.

Simultaneous targeting of multiple domains of HER2 and EGFR using domain-specific alpha particle labeled radioimmunoconjugates

Alpha particle-labeled antibody-drug radioconjugates for radiotherapy of metastatic colorectal cancer (mCRC)

Frequent collaborators

Humphrey Fonge

Maruti Uppalapati

Maruti Uppalapati

Mohan Babu

Nicolas Bisson

Andrew Freywald

Anthony Kusalik